Alnylam Pharmaceuticals · 5 days ago
Executive Director, Head of Search & Evaluation, Business Development
Cambridge, MA
Full-time
Hybrid
Director/Executive
$280K/yr - $380K/yr
10+ years expAlnylam Pharmaceuticals is a leader in RNAi therapeutics, and they are seeking an experienced business development leader with deep scientific expertise to source and evaluate external innovation. The role involves collaborating with cross-functional teams, building relationships with external partners, and managing a team of business development professionals to drive strategic initiatives.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Hiring Manager
Jill Donovan
Responsibilities
Demonstrate leadership and scientific acumen while collaborating closely with cross-functional teams including R&D, Commercial, Finance, and BD Transactions to identify and assess external innovation for Alnylam governance endorsement, including leading scientific evaluations and due diligence in support of BD opportunity review, prioritization, and decision-making
Build and maintain strong relationships with external partners, including biotechnology and pharmaceutical companies, academic institutions, venture capitalists, and other stakeholders
Serve as thought partner to facilitate and support formulation of BD strategies to drive toward enterprise goals and objectives while sourcing and evaluating external innovation
Communicate effectively both internally across a matrix organization and externally with potential partners by articulating the vision, purpose, and expectations of the BD initiatives to ensure clarity and alignment
As part of the BD Leadership Team, manage or coach a team of BD professionals and foster a culture of excellence, innovation, and collaboration
Qualification
Required
An advanced degree in the biomedical field such as MD, PhD, and PharmD required
At least 10+ years of relevant industry experience in biotechnology and pharmaceutical BD, consulting, venture capital, or investment banking
Extensive experience in sourcing external innovation and leading scientific due diligence to support the execution of complex and high-value transactions. Deal sheet specifics required
Deep understanding of the drug development processes from discovery to regulatory approval and knowledge of biotechnology and pharmaceutical industries, including market trends, regulatory environment, and their business impact
Demonstrated ability to simplify complex ideas / concepts, synthesize and summarize a complex set of facts and opportunities within the broader strategic context as well as proven track record to exert influence, facilitate candid dialogue find solutions and gain alignment
Excellent communication, presentation, and problem-solving skills, with the proven ability to influence and persuade internal and external stakeholders at all levels
Highly collaborative, team-oriented, and adaptable, with the ability to work effectively in a fast-paced and dynamic environment
Proven ability to manage multiple projects efficiently with a high degree of independence and purposed urgency
Strong executive presence, leadership, and people management skills, with the ability to inspire and motivate others
Benefits
Comprehensive benefits including medical, dental, and vision coverage
Life and disability insurance
A lifestyle reimbursement program
Flexible spending and health savings accounts
A 401(k) with a generous company match
Paid time off
Wellness days
Holidays
Two company-wide recharge breaks
Generous family resources and leave
Company
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
1001-5000 employees
H1B Sponsorship
Alnylam Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2022 (18)
2021 (19)
2020 (7)
Funding
Current Stage
Public CompanyTotal Funding
$4.55BKey Investors
Blackstone Life SciencesBlackstone CreditRegeneron
2025-09-09Post Ipo Debt· $661.25M
2022-09-12Post Ipo Debt· $900M
2022-03-04IPO
Leadership Team
Yvonne Greenstreet
Chief Executive Officer
Jeff Poulton
Chief Financial Officer
Recent News
Longevity.Technology
2026-01-14
2026-01-13
Company data provided by crunchbase